ReviewInternational journal of molecular sciences2019
Encapsulating Peritoneal Sclerosis: Pathophysiology and Current Treatment Options.
Review in International journal of molecular sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 2 syntheses or guidelines pooled it, 85 citations in OpenAlex.
- Risk factors for Encapsulating Peritoneal Sclerosis in patients undergoing peritoneal dialysis: A meta-analysis.PloS one · 2022Pooled it
- Mechanisms of Peritoneal Fibrosis: Focus on Immune Cells-Peritoneal Stroma Interactions.Frontiers in immunology · 2021Pooled it
- Protecting peritoneal dialysis patients: evaluation and prevention strategies for noninfectious risk factors.Renal failure · 2026Review
- Case report: abdominal cocoon syndrome following peritoneal dialysis presenting as closed-loop small bowel obstruction.Journal of surgical case reports · 2026Article
- Mesothelial cell senescence induced by high glucose in peritoneal dialysis drives fibroblast activation and peritoneal fibrosis through KLF6-mediated activation of TGF-β pathway.Molecular and cellular biochemistry · 2026Article
- Encapsulating peritoneal sclerosis: a three-case series highlighting diagnostic challenges and surgical managements.International journal of surgery case reports · 2026Article
- Association between serum potassium levels and peritonitis in peritoneal dialysis patients: a longitudinal study.BMC nephrology · 2026Observational
- Anti-fibrotic effect ofFrontiers in bioengineering and biotechnology · 2026Article
- Article
- Entrapped in the Cocoon: A Rare Case of Sclerosing Encapsulating Peritonitis in a Patient on Dialysis.Cureus · 2025Article
- Text mining for case report articles on "peritoneal dialysis" from PubMed database.Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy · 2025Article
- Unraveling the enigma of sclerosing encapsulating peritonitis: a comprehensive review.Annals of coloproctology · 2025Article
- Integrative Analysis of Drug Co-Prescriptions in Peritoneal Dialysis Reveals Molecular Targets and Novel Strategies for Intervention.Journal of clinical medicine · 2025Article
- Prevention and Treatment of Peritoneal Dialysis-Associated Fibrosis with Intraperitoneal Anti-Fibrotic Therapy in Experimental Peritoneal Fibrosis.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Peritoneal Dialysis -Associated Fibrosis: Emerging Mechanisms and Therapeutic Opportunities.Frontiers in pharmacology · 2025Review
- Role of biomarker SOCS1 in peritoneal dialysis-associated peritoneal fibrosis and immune infiltration based on machine learning screening.Frontiers in pharmacology · 2025Article
- Encapsulating Peritoneal Sclerosis Leading to Small Bowel Obstruction in a Young Woman with End-Stage Renal Disease: A Case Report.The American journal of case reports · 2024Article
- Intraoperative Diagnosis and Surgical Management of Encapsulating Peritoneal Sclerosis: A Case Report.Cureus · 2024Article
- BMSC-derived Exosomes Ameliorate Peritoneal Dialysis-associated Peritoneal Fibrosis via the Mir-27a-3p/TP53 Pathway.Current medical science · 2024Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Encapsulating peritoneal sclerosis (EPS) is a life-threatening complication of long-term peritoneal dialysis (PD), which may even occur after patients have switched to hemodialysis (HD) or undergone kidney transplantation. The incidence of EPS varies across the globe and increases with PD vintage. Causative factors are the chronic exposure to bioincompatible PD solutions, which cause long-term modifications of the peritoneum, a high peritoneal transporter status involving high glucose concentrations, peritonitis episodes, and smoldering peritoneal inflammation. Additional potential causes are predisposing genetic factors and some medications. Clinical symptoms comprise signs of intestinal obstruction and a high peritoneal transporter status with incipient ultrafiltration failure. In radiological, macro-, and microscopic studies, a massively fibrotic and calcified peritoneum enclosed the intestine and parietal wall in such cases. Empirical treatments commonly used are corticosteroids and tamoxifen, which has fibrinolytic properties. Immunosuppressants like azathioprine, mycophenolate mofetil, or mTOR inhibitors may also help with reducing inflammation, fibrin deposition, and collagen synthesis and maturation. In animal studies, N-acetylcysteine, colchicine, rosiglitazone, thalidomide, and renin-angiotensin system (RAS) inhibitors yielded promising results. Surgical treatment has mainly been performed in severe cases of intestinal obstruction, with varying results. Mortality rates are still 25-55% in adults and about 14% in children. To reduce the incidence of EPS and improve the outcome of this devastating complication of chronic PD, vigorous consideration of the risk factors, early diagnosis, and timely discontinuation of PD and therapeutic interventions are mandatory, even though these are merely based on empirical evidence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.